Skip to content

Evaluation of the Effect of TMS on Primary Dysmenorrhea

Based on Functional Magnetic Resonance Imaging Technology to Evaluate the Analgesic Effect of TMS on Primary Dysmenorrhea and Neuroimaging Prediction Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04168489
Enrollment
80
Registered
2019-11-19
Start date
2022-07-20
Completion date
2024-07-30
Last updated
2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Dysmenorrhea

Keywords

rTMS, Primary Dysmenorrhea

Brief summary

Based on the pain threshold and visual simulation score, primary dysmenorrhea patients will be divided into treatment effective group or non-effective group.According to the functional magnetic resonance imaging, the investigators investigate whether there is characteristic or secondary brain features before and after rTMS intervention.

Detailed description

Long term primary dysmenorrhea may induce a series of disorders involving psychology, lower quality of life, or even developing chronic organic lesion or chronic pain. Effective symptom improvement is urgently needed. During the Non-pharmaceutical interventions, repetitive transcranial magnetic stimulation (rTMS) is received preliminary approval because of its noninvasive and safe analgesic effect. In this randomized single blind longitudinal study, the investigators investigate the analgesic effect of rTMS in long term moderate-to-severe primary dysmenorrhea women. Based on the pain threshold and visual simulation score, primary dysmenorrhea patients will be divided into treatment effective group or non-effective group. According to the functional magnetic resonance imaging, the investigators investigate whether there is characteristic or secondary brain features before and after rTMS intervention. By combining pre and post performances of the degree of dysmenorrhea, behavioral data and sensitive hematological indicators, the investigators intend to build an association model between brain and pain development curve. Using correlation and multiple regression analysis method, the investigators intend to find sensitive neuroimaging biomarkers in predicting the analgesic effect of rTMS. The current study is not only contributing to improve the central nervous systematic mechanism of rTMS in chronic pelvic pain, but also significant for clinical effective treatment based on neuroimaging predictive markers.

Interventions

DEVICEactive rTMS

(rTMS) is received preliminary approval because of its noninvasive and safe analgesic effect.

DEVICEsham rTMS

The sham rTMS is inactive and similar to placebo effect.

Sponsors

First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

(a) consistent with the diagnostic criteria for primary dysmenorrhea according to the American College of Obstetricians and Gynecologists; (b) regular menstrual cycles (27-32 days); and (c) the average intensity of dysmenorrhoeic pain in the past 6 months should be rated ≥4 on a visual analogue scale (VAS) (0 = no pain, 10 = the worst imaginable pain).

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* consistent with the diagnostic criteria for primary dysmenorrhea according to the American College of Obstetricians and Gynecologists; * regular menstrual cycles (27-32 days); * the average intensity of dysmenorrhoeic pain in the past 6 months should be rated ≥4 on a visual analogue scale (VAS) (0 = no pain, 10 = the worst imaginable pain).

Exclusion criteria

* organic pelvic disease; * using oral contraceptives, hormonal supplements, Chinese traditional medicine or any central-acting medication (e.g., opioids, anti-epileptics) within 6 months before the study; * comorbid chronic pain states; * alcohol, nicotine or drug addiction; * neurologic disease or psychiatric disorder; * history of childbirth; * a positive pregnancy test or immediate plans for pregnancy; * any MRI contraindications. In addition, no analgesics were consumed 24 hours prior to the experiment.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of effect of rTMS for primary dysmenorrheaFrom 1 month before treatment to 3 months after treatment for each volunteers(through study completion, an average of 2 years)Assessments using Visual Analog Score for pain(Units on a Scale) in primary dysmenorrhea during menstrual phase to evaluate the effect of rTMS

Countries

China

Contacts

Primary Contactwanghuan Dun, M.D.
wanghuandun@163.com0086-18092706568
Backup Contactke wang, M.D.
1740923504@qq.com15529620760

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026